ictastan 200 mg/245 mg film-coated tablets
actavis group ptc ehf - emtricitabine; tenofovir disoproxil - film-coated tablet - 200/245 milligram(s) - antivirals for treatment of hiv infections, combinations; tenofovir disoproxil and emtricitabine
ictastan tablet, film coated 200mg/245mg
actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - emtricitabine, tenofovir disoproxil - film-coated tablet - emtricitabine 200 mg tenofovir disoproxil 245 mg - antivirals for systemic use
ictastan 200 mg/245 mg film-coated tablets
accord healthcare ireland ltd. - emtricitabine; tenofovir disoproxil - film-coated tablet - 200 mg/245 milligram(s) - antivirals for treatment of hiv infections, combinations; tenofovir disoproxil and emtricitabine
ictastan 200mg/245mg, filmomhulde tabletten
ictastan 200mg/245mg tablets
accord-uk ltd - tenofovir disoproxil; emtricitabine - oral tablet - 245mg ; 200mg
erlotinib taro 100 mg
taro international ltd, israel - erlotinib as hydrochloride - film coated tablets - erlotinib as hydrochloride 100 mg - erlotinib - non-small cell lung cancer (nsclc): erlotinib taro is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations. erlotinib taro is indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations and stable disease after first-line chemotherapy. erlotinib taro is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.pancreatic cancer: erlotinib taro is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
erlotinib taro 150 mg
taro international ltd, israel - erlotinib as hydrochloride - film coated tablets - erlotinib as hydrochloride 150 mg - erlotinib - non-small cell lung cancer (nsclc): erlotinib taro is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations. erlotinib taro is indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations and stable disease after first-line chemotherapy. erlotinib taro is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.pancreatic cancer: erlotinib taro is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
erlotinib taro 25 mg
taro international ltd, israel - erlotinib as hydrochloride - film coated tablets - erlotinib as hydrochloride 25 mg - erlotinib - non-small cell lung cancer (nsclc): erlotinib taro is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations. erlotinib taro is indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations and stable disease after first-line chemotherapy. erlotinib taro is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.pancreatic cancer: erlotinib taro is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
venaforce varicose veins gastro-resistant tablets
a.vogel ireland limited - extract (as dry extract) from fresh horse chesnut seeds (aesculus hippocastanum l. semen) - gastro-resistant tablet - .
venaforce horse chestnut tablets gastro-resistant
bioforce (uk) ltd - extract (as dry extract) from fresh horse chesnut seeds (aesculus hippocastanum l. semen) - tablets gastro-resistant - 157.5-225.0 milligram